| Sumario: | The purpose of this issue is to present the impact in clinical practice as well as in medical research of novel molecules that have been introduced in the treatment of diabetes mellitus, dyslipidemia, and cardiovascular disease. The topic focuses on the improvements in disease outcomes as well as the numerous beneficial effects of use of certain medications such as GLP-1 agonists, dual GLP-1/ GIP agonists, and SGLT-2 inhibitors for diabetes mellitus treatment; PCSK9 inhibitors and small interfering RNA (siRNA) molecules for dyslipidemia; and antiaggregants, oral anticoagulants, scubitril/valsartan, and non-steroidal mineralocorticoid receptor agonists or dapagliflozin in cardiovascular diseases. We believe that the number of real-life studies and in vivo and in vitro research of the effects of these drugs is quite low at the moment, leading to a lack of understanding of the complex molecular effects and pleiotropic effects of these medications, as well as incomplete knowledge regarding the repurposing of these drugs in clinical practice. Thus, this Special Issue is incredibly topical and important, and we look forward to your submissions which will help to clarify the issues surrounding such drugs.
|
|---|
